Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
This is a phase II study of Bevacizumab plus Temodar and Tarceva in patients with
non-progressive glioblastoma or gliosarcoma. Patients must have stable disease immediately
following a standard course of up-front radiotherapy and Temodar. All patients will receive
Bevacizumab, Temodar and Tarceva. A total of 60 patients will be enrolled. Our hypothesis is
that the combination of Bevacizumab plus Temodar and Tarceva will increase survival over that
seen in historical controls who have newly diagnosed, non-progressive glioblastoma or
gliosarcoma following radiotherapy plus Temodar and use Temodar alone.